$2.42 Billion is the total value of Rock Springs Capital Management LP's 131 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BIIB | New | BIOGEN INC | $56,948,000 | – | 180,000 | +100.0% | 2.36% | – |
| INSP | New | INSPIRE MED SYS INC | $12,056,000 | – | 200,000 | +100.0% | 0.50% | – |
| New | CYTOKINETICS INCnote 4.000%11/1 | $10,573,000 | – | 8,000,000 | +100.0% | 0.44% | – | |
| CNMD | New | CONMED CORP | $10,309,000 | – | 180,000 | +100.0% | 0.43% | – |
| PPD | New | PPD INC | $8,015,000 | – | 450,000 | +100.0% | 0.33% | – |
| IMRA | New | IMARA INC | $7,148,000 | – | 445,936 | +100.0% | 0.30% | – |
| XENE | New | XENON PHARMACEUTICALS INC | $5,670,000 | – | 500,000 | +100.0% | 0.23% | – |
| PRTA | New | PROTHENA CORP PLC | $5,350,000 | – | 500,000 | +100.0% | 0.22% | – |
| STAA | New | STAAR SURGICAL CO | $5,000,000 | – | 155,000 | +100.0% | 0.21% | – |
| ALLO | New | ALLOGENE THERAPEUTICS INC | $4,860,000 | – | 250,000 | +100.0% | 0.20% | – |
| IMVT | New | IMMUNOVANT INC | $3,891,000 | – | 250,000 | +100.0% | 0.16% | – |
| PASG | New | PASSAGE BIO INC | $3,544,000 | – | 225,000 | +100.0% | 0.15% | – |
| New | TRILLIUM THERAPEUTICS INC | $3,030,000 | – | 750,000 | +100.0% | 0.12% | – | |
| GWPH | New | GW PHARMACEUTICALS PLCads | $2,627,000 | – | 30,000 | +100.0% | 0.11% | – |
| New | RETROPHIN INCnote 2.500% 9/1 | $2,566,000 | – | 3,250,000 | +100.0% | 0.11% | – | |
| XLRN | New | ACCELERON PHARMA INC | $1,573,000 | – | 17,500 | +100.0% | 0.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.